Sk Biopharmaceuticals Co Ltd (326030) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Sk Biopharmaceuticals Co Ltd (KRX:326030), currently being evaluated. In 2025, Sk Biopharmaceuticals Co Ltd generated $706.74 Billion in revenue and $146.82 Billion in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Sk Biopharmaceuticals Co Ltd is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $706.74 Billion
- Free Cash Flow (2025): $146.82 Billion
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.